Organic cation transporter pharmacogenomics and drug–drug interaction

References

• Kirchheiner J, Schwab M. Heterogeneity of drug responses and individualization of therapy. In: Pharmacology and Therapeutics. Principles to Practice. Waldman SA, Terzic A (Eds). Elsevier, Amsterdam, The Netherlands 225–238 (2008).
   Google Scholar
• Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet.5(9), 669–676 (2004).
   PubMed Web of Science ®Google Scholar
• Yee SW, Chen L, Giacomini KM. Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics11(4), 475–479 (2010).
   Google Scholar
• Nies AT, Schwab M, Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin. Drug Metab. Toxicol.4, 545–568 (2008).
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ et al. Membrane transporters in drug development. Nat. Rev. Drug Discov.9(3), 215–236 (2010).
   PubMed Web of Science ®Google Scholar
• Kerb R, Schwab M. ADME pharmacogenetics and its impact on drug–drug interactions. In: Enzyme- and Transporter-Based Drug–Drug Interactions: Progress and Future Challenges. Pang KS, Rodrigues AD, Peter RM (Eds). Springer, MI, USA 51–74 (2010).
   Google Scholar
• Neuhoff S, Ungell AL, Zamora I, Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug–drug interactions. Pharm. Res.20(8), 1141–1148 (2003).
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res.24(7), 1227–1251 (2007).
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol.16(7), 871–881 (1997).
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Winter S et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology50(4), 1227–1240 (2009).
   PubMed Web of Science ®Google Scholar
• M üller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol.70(12), 1851–1860 (2005).
   Google Scholar
• Lips KS, Volk C, Schmitt BM et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am. J. Respir. Cell Mol. Biol.33(1), 79–88 (2005).
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol.13(4), 866–874 (2002).
   PubMed Web of Science ®Google Scholar
• Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch. Pharmacol.376(6), 449–461 (2008).
   PubMed Web of Science ®Google Scholar
• Verhaagh S, Schweifer N, Barlow DP, Zwart R. Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics55(2), 209–218 (1999).
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. In: Handb. Exp. Pharmacol. Fromm MF, Kim RB (Eds). Springer, MI, USA (2010).
   Google Scholar
• Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J. Biol. Chem.277(25), 22491–22496 (2002).
   PubMed Web of Science ®Google Scholar
• Takeda M, Khamdang S, Narikawa S et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther.300(3), 918–924 (2002).
   PubMed Web of Science ®Google Scholar
• Jung N, Lehmann C, Rubbert A et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral therapy in HIV infection. Drug Metab. Dispos.36(8), 1616–1623 (2008).
   PubMed Web of Science ®Google Scholar
• Minuesa G, Volk C, Molina-Arcas M et al. Transport of lamivudine (3TC) and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J. Pharmacol. Exp. Ther.329(1), 252–261 (2009).
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet.20(5), 379–386 (2005).
   PubMedGoogle Scholar
• Hasannejad H, Takeda M, Narikawa S et al. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Eur. J. Pharmacol.499(1–2), 45–51 (2004).
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui KI. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and MATE family). J. Pharmacol. Exp. Ther.319(2), 879–886 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res.66(17), 8847–8857 (2006).
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest.117(5), 1422–1431 (2007).
   PubMed Web of Science ®Google Scholar
• Kerb R, Brinkmann U, Chatskaia N et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics12(8), 591–595 (2002).
   PubMedGoogle Scholar
• Shu Y, Leabman MK, Feng B et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl Acad. Sci. USA100(10), 5902–5907 (2003).
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro R et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther.83(2), 273–280 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly LA, Kimber CH et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes58(6), 1434–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Song IS, Shin HJ, Shim EJ et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther.84(5), 559–562 (2008).
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics18(7), 637–645 (2008).
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S, Brown C et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics19(7), 497–504 (2009).
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther.86(3), 299–306 (2009).
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther.86(4), 396–402 (2009).
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Deuster D, Knief A et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is target for protective interventions. Am. J. Pathol.176(3), 1169–1180 (2010).
   PubMed Web of Science ®Google Scholar
• Eeles RA, Kote-Jarai Z, Giles GG et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet.40(3), 316–321 (2008).
   PubMedGoogle Scholar
• Tregouet DA, Konig IR, Erdmann J et al. Genome-wide haplotype association study identifies the SLC22A3–LPAL2–LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet.41(3), 283–285 (2009).
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Eichelbaum M, Brinkmann U et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet358(9279), 383–384 (2001).
   PubMed Web of Science ®Google Scholar
• Tachampa K, Takeda M, Khamdang S et al. Interactions of organic anion transporters and organic cation transporters with mycotoxins. J. Pharmacol. Sci.106(3), 435–443 (2008).
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Endou H et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther.315(1), 337–345 (2005).
   PubMed Web of Science ®Google Scholar
• Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on OATPs and OCT1. Diabetes57(6), 1463–1469 (2008).
   PubMed Web of Science ®Google Scholar
• Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3 in vitro and implications for drug–drug interactions. Xenobiotica38(9), 1203–1218 (2008).
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica38(7–8), 676–708 (2008).
   PubMed Web of Science ®Google Scholar
• Kindla J, Fromm MF, König J. In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions. Expert Opin. Drug Metab. Toxicol.5(5), 489–500 (2009).
   PubMed Web of Science ®Google Scholar
• Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol.23(5), 545–551 (1987).
   PubMed Web of Science ®Google Scholar
• Moore KH, Yuen GJ, Raasch RH et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim–sulfamethoxazole. Clin. Pharmacol. Ther.59(5), 550–558 (1996).
   PubMed Web of Science ®Google Scholar
• Tanihara Y, Masuda S, Katsura T, Inui KI. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem. Pharmacol.78(9), 1263–1271 (2009).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit.26(2), 180–185 (2004).
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8), 789–799 (2008).
   PubMed Web of Science ®Google Scholar